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CliOBJECTIVES The aim of this study was to investigate the vascular responses and fates of the scaffold after
bioresorbable vascular scaffold (BVS) implantation using multimodality imaging.
BACKGROUND Serial comprehensive image assessments after BVS implantation in the context of a randomized trial
have not yet been reported.
METHODS In the ABSORB Japan trial, 400 patients were randomized to a BVS (n ¼ 266) or a cobalt-chromium
everolimus-eluting stent (n ¼ 134). Through 3 years, patients underwent serial angiography and intravascular ultrasound
or optical coherence tomography (OCT).
RESULTS Luminal dimension at 3 years was consistently smaller with the BVS than with the cobalt-chromium
everolimus-eluting stent (mean angiographic minimal luminal diameter 2.04  0.63 mm vs. 2.40  0.56 mm, mean
difference 0.37 mm [95% conﬁdence interval: 0.50 to 0.24 mm]; p < 0.001), mainly because of smaller device area
(6.13  2.03 mm2 vs. 7.15  2.16 mm2, mean difference 1.04 mm2 [95% conﬁdence interval: 1.66 to 0.42 mm2];
p < 0.001), and larger neointimal area (2.10  0.61 mm2 vs. 1.86  0.64 mm2, mean difference 0.24 mm2 [95% con-
ﬁdence interval: 0.06 to 0.43 mm2]; p ¼ 0.01) by OCT. BVS-treated vessels did not show previously reported favorable
vessel responses, such as positive vessel remodeling, late luminal enlargement, and restoration of vasomotion, although
the OCT-based healing score was on average zero (interquartile range: 0.00 to 0.00). At 3 years, intraluminal scaffold
dismantling (ISD) was observed in 14% of BVS. On serial OCT, ISD was observed in 6 lesions at 2 years, where the struts
had been fully apposed at post-procedure, while ISD was observed in 12 lesions at 3 years, where 8 lesions were free from
ISD on 2-year OCT. In 5 cases of very late scaffold thrombosis, strut discontinuities were detected in all 4 cases with
available OCT immediately before reintervention.
CONCLUSIONS In this multimodality serial imaging study, luminal dimension at 3 years was smaller with the BVS than
with the cobalt-chromium everolimus-eluting stent. ISD, suspected to be one of the mechanisms of very late BVS
thrombosis, was observed in a substantial proportion of cases at 3 years, which developed between post-procedure and 2
years and even beyond 2 years. (AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 [Absorb BVS] in Japanese
Population [ABSORB JAPAN]; NCT01844284) (J Am Coll Cardiol Intv 2020;13:116–27) © 2020 The Authors. Published
by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 1936-8798 https://doi.org/10.1016/j.jcin.2019.09.047
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117AB BR E V I A T I O N S
AND ACRONYM S
BVS = bioresorbable vascular
scaffold(s)
CoCr-EES = cobalt-chromium
everolimus-eluting stent(s)
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasoundA drug-eluting stent (DES) prevents repeatrevascularization more efﬁciently than abare-metal stent and is currently a standard
treatment device in percutaneous coronary interven-
tion (1). However, the permanent presence of metallic
foreign material could cause late complications such
as metallic stent fractures, late restenosis, and neoa-
therosclerosis (2,3), resulting in a steady increase of
stent-related events in the long term (4).SEE PAGE 128 OCT = optical coherence
tomography
PSP = pre-dilatation,
appropriate sizing, and post-
dilatation
QCA = quantitative coronary
angiographic
TLF = target lesion failure
TLR = target lesion
revascularizationFully bioresorbable scaffolds were designed to
mitigate the potential long-term adverse effect of
metallic DES (5). The device offers transient scaf-
folding of the dilated coronary vessel to prevent acute
recoil and abrupt vessel closure, elutes an anti-
proliferative drug to prevent neointimal hyperplasia,
and ultimately disappears through bioresorption. Af-
ter bioresorption, the vessel may recover physiolog-
ical functions such as mechanotransduction, cyclic
strain, and vasomotion, which theoretically could
lower the risk for long-term event (6,7).
The polylactic bioresorbable everolimus-eluting
Absorb vascular scaffold (Abbott Vascular, Santa
Clara, California) received its Conformité Européenne
mark in 2010 and was approved by the U.S. Food and
Drug Administration in the United States and the
Pharmaceuticals and Medical Devices Agency in
Japan on the basis of the reported noninferiority of
the bioresorbable vascular scaffold (BVS) to the
cobalt-chromium everolimus-eluting stent (CoCr-
EES) at 1 year in the pivotal trials (8,9). However,
long-term clinical results from these pivotal trials
demonstrated that there were higher risks for device
thrombosis with the BVS than with the CoCr-EES
during the time period when bioresorption was still
ongoing (10). The safety concerns raised by these re-
sults and the low market share of the device forced
the manufacturer to discontinue marketing the
device. Nevertheless, to improve bioresorbable scaf-
folds further, it is essential to investigate the long-
term behavior of the BVS using intravascularMedical Center, Boston, Massachusetts; pColumbia University Medical Cent
vascular Research Foundation, New York, New York; and the qInternationa
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Manuscript received April 12, 2019; revised manuscript received Septemberimaging and to identify potential mecha-
nisms of late failures of the current BVS such
as device thrombosis. Previous imaging
studies up to 5 years after BVS implantation
have suggested favorable vascular responses,
including restoration of vasomotion and
endothelium-dependent vasodilation, late
luminal enlargement with plaque regression,
and positive vessel remodeling, and the for-
mation of a stable-appearing neointima
(11–13). However, these studies were single-
arm studies including relatively small
numbers of patients, and no previous imag-
ing study has compared vessel responses af-
ter BVS implantation with those after metallic
DES implantation. Therefore, we conducted a
comprehensive serial imaging study using
angiography, optical coherence tomography
(OCT) and intravascular ultrasound (IVUS)
up to 3 years after BVS compared with CoCr-EES
implantation in the randomized ABSORB Japan
trial.
METHODS
STUDY DESIGN AND POPULATION. ABSORB Japan
was a prospective, multicenter, randomized, single-
blind, active-controlled clinical trial randomizing
400 patients in a 2:1 ratio to treatment with the
BVS (n ¼ 266) or the CoCr-EES (n ¼ 134). The
details of the trial have been published elsewhere
(9). The primary endpoint of the present study was
target lesion failure (TLF) at 12 months, whereas
the imaging investigations and analysis at 3 years
were pre-speciﬁed per protocol (9). The patients
were subrandomized into 3 imaging groups: the
OCT-1 subgroup (n ¼ 125) with serial OCT at post-
implantation, 2 years, and 3 years; the OCT-2
group (n ¼ 125) with OCT only at 3 years; and
the IVUS subgroup (n ¼ 150) with IVUS at post-
implantation and 3 years. Quantitative coronary
angiographic (QCA) analysis was performed ater, NewYork-Presbyterian Hospital, and the Cardio-
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rt. The corresponding author had full access to the
the study and the decision to submit for publication.
ular. Dr. Stone is chairman of the advisory board of
nd personal fees from Abbott Vascular. Drs. Namiki,
l fees for advisory agreements with Abbott Vascular
r. All other authors have reported that they have no
9, 2019, accepted September 23, 2019.
FIGURE 1 Kaplan-Meier Curves Representing the Estimated Cumulative Incidences of Clinical Endpoints
(A) Target lesion failure (TLF), (B) target vessel myocardial infarction (TV-MI), (C) ischemia-driven target lesion revascularization (ID-TLR), and (D) device (stent/
scaffold) thrombosis. BVS ¼ bioresorbable vascular scaffold; CI ¼ conﬁdence interval; Co-Cr EES ¼ cobalt-chromium everolimus-eluting stent; HR ¼ hazard ratio.
Continued on the next page
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118baseline, 13 months, and 3 years in all patients and
at 2 years in the OCT-1 subgroup (Online Figure S1).
The ethics committees approved the protocol at all
participating institutions. All patients provided
written informed consent and were blinded to their
treatment assignment through 5-year follow-up. All
patients were maintained on a thienopyridine for at
least 12 months and aspirin indeﬁnitely.
CLINICAL ENDPOINTS AND DEFINITIONS. Death,
myocardial infarction, target lesion revascularization
(TLR) or target vessel revascularization and stent or
scaffold thrombosis were adjudicated by an inde-
pendent blinded clinical events committee (Harvard
Clinical Research Institute, Boston, Massachusetts).
Independent study monitors veriﬁed all case report
forms on site. A Data and Safety Monitoring Board
monitored patient safety. Deﬁnitions of stent or
scaffold thrombosis and other endpoints were based
on the Academic Research Consortium criteria (14).
TLF was deﬁned as a composite of cardiac
death, target vessel myocardial infarction, andischemia-driven TLR. A complete list of endpoints is
provided elsewhere (9).
DEVICE IMPLANTATION AND IMAGING FOLLOW-UP.
The details of the implantation technique were pre-
viously described (9). The proportion of optimal im-
plantation technique, so-called PSP (a combination of
pre-dilatation, appropriate sizing, and post-
dilatation) was evaluated stratiﬁed to each imaging
subgroup. At follow-up, coronary angiography was
repeated in the same angiographic views as at post-
procedure. IVUS and OCT were performed in the
target lesion including 5 mm distal and proximal to
the stent or scaffold. The imaging data were analyzed
by the independent core laboratories (quantitative
coronary angiography: Beth Israel Deaconess Medical
Center, Boston, Massachusetts; IVUS: Stanford Uni-
versity, Stanford, California; and OCT: Cardialysis,
Rotterdam, the Netherlands). In patients with interim
TLR, pre-TLR QCA data were carried forward up to
the 3-year follow-up QCA study for the nonserial
analysis, while for the serial analysis, pre-TLR QCA
FIGURE 1 Continued
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119data were carried forward only to the next follow-up
QCA study.
The details of IVUS and optical coherence tomo-
graphic analysis methods are described in the Online
Appendix. In serial IVUS and optical coherence
tomographic analysis, cases with interim TLR were
excluded because of the presence of a nonstudy
device.
OCT endpoints included the mean and minimal in-
device luminal area, the mean and maximum neo-
intimal hyperplasia area, the mean device area, and
the percentage of malapposed struts (15). IVUS end-
points included mean areas of vessel, stent or scaf-
fold, and neointima and mean and minimal areas of
the lumen, which were measured in the device
segment using validated software (echoPlaque, Indec
Systems, Los Altos, CA). At 3 years, scaffold area of
the BVS was not measured, because of limited visi-
bility of struts due to bioresorption of the device.
Strut discontinuities were assessed on OCT as the
presence of overhang or stacked struts, categorized
into 4 groups from high to low ranking: “uncovered
and malapposed,” “uncovered and apposed,”“covered and malapposed,” and “covered and
apposed.” If more than 1 condition was present in 1
lesion, the lesionwas classiﬁedwith theworst ranking.
STATISTICAL ANALYSIS. The clinical endpoint was
evaluated in the intent-to-treat population, whereas
the imaging endpoint was evaluated speciﬁcally in a
population excluding patients who did not receive
the assigned treatment. For binary variables, counts,
percentages, and 95% conﬁdence intervals were
calculated. Pearson’s chi-square test or the Fisher
exact test were performed as appropriate. Continuous
variables are presented as mean  SD or as median
(interquartile range) and were compared using Stu-
dent’s t-test or a Wilcoxon rank sum test on the basis
of the distributions. Paired numeric data obtained in
the serial imaging studies were compared using the
paired t-test. For time-to-event variables, survival
curves were constructed using Kaplan-Meier esti-
mates to demonstrate the cumulative incidences and
were compared using the log-rank test. All statistical
analyses were performed using SAS versions 9.2 and
9.3 (SAS Institute, Cary, North Carolina).
TABLE 1 Nonserial Results of Quantitative Coronary Angiography, Intravascular Ultrasound, and optical Coherence Tomography at
Baseline and at 3 Years
BVS CoCr-EES
p ValueNumber of Lesions Number of Lesions
QCA
Lesion length, mm
Pre-procedure 272 13.5  5.28 137 13.3  5.52 0.78
Reference vessel diameter, mm
Pre-procedure 272 2.72  0.44 137 2.79  0.46 0.11
Post-procedure 272 2.76  0.42 137 2.85  0.43 0.04
At 13 months 260 2.70  0.42 129 2.80  0.44 0.046
At 3 yrs 238 2.70  0.43 119 2.81  0.45 0.03
MLD, mm
Pre-procedure 272 0.96  0.33 137 0.99  0.36 0.42
Post-procedure* 272 2.42  0.38 137 2.64  0.40 <0.0001
At 13 months* 260 2.23  0.47 129 2.48  0.53 <0.0001
At 3 yrs* 238 2.04  0.63 119 2.40  0.56 <0.0001
DS, %
Pre-procedure 272 64.6  11.2 137 64.7  10.9 0.93
Post-procedure* 272 11.8  7.4 137 7.1  8.0 <0.0001
At 13 months* 260 17.4  12.8 129 11.7  12.3 <0.0001
At 3 yrs* 238 24.9  19.0 119 14.7  14.8 <0.0001
Late lumen loss (in-device), mm
At 13 months* 260 0.19  0.31 129 0.16  0.33 0.35
At 3 yrs* 238 0.39  0.55 119 0.23  0.42 0.003
Nitrate vasoreactivity test at 3 yrs, mm
Mean luminal diameter pre-NTG* 219 2.48  0.52 110 2.82  0.49 <0.001
Mean luminal diameter post-NTG* 220 2.54  0.52 112 2.88  0.48 <0.001
Absolute change* 218 0.06  0.15 110 0.06  0.11 0.70
IVUS
Mean vessel area, mm2
Post-procedure 77 13.69  4.51 41 14.61  5.04 0.33
At 3 yrs 70 13.42  4.49 37 14.95  4.99 0.12
Mean scaffold/stent area, mm2
Post-procedure 97 6.48  2.00 47 7.33  2.12 0.02
At 3 yrs — NA 43 7.70  2.37 NA
Mean total plaque area, mm2
Post-procedure 77 7.29  2.72 41 7.36  3.13 0.91
At 3 yrs 70 7.49  2.33 37 8.14  3.09 0.27
Mean luminal area, mm2
Post-procedure 97 6.49  2.00 47 7.35  2.14 0.02
At 3 yrs 86 6.13  2.41 43 6.83  2.29 0.11
Absolute change 83 0.45  1.28 41 0.67  0.98 0.30
Minimum luminal area, mm2
Post-procedure 97 5.39  1.80 47 6.32  2.04 0.009
At 3 yrs 86 4.56  2.06 43 5.23  2.11 0.09
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120RESULTS
BASELINE CHARACTERISTICS AND CLINICAL OUTCOMES.
The study ﬂowchart for clinical follow-up and the
baseline characteristics are presented in Online
Figure S1 and Online Tables S1, S2, and S3. Eight pa-
tients in BVS arm and 4 patients in CoCr-EES arm
withdrew their consent. In total, 96.5% had 3-year
clinical follow-up (median 1,098 days; interquartile
range: 1,085 to 1,110 days). At 3 years, 40.5% of pa-
tients were on dual-antiplatelet therapy (BVS 41.7%
vs. CoCr-EES 38.1%). Clopidogrel was predominantly
used as a P2Y12 inhibitor, while prasugrel was used in7 and 6 patients in the BVS and CoCr-EES
arms, respectively.
The PSP criteria were achieved in only 16 lesions
(5.8%) in the BVS arm at the time of the procedure (7
lesions [8.1%] in the IVUS subgroup and 8 lesions
[6.1%] in the OCT subgroup).
The cumulative 3-year incidence of TLF was
numerically higher in the BVS arm than in the CoCr-
EES arm (8.9% vs. 5.5%; p ¼ 0.23) (Figure 1, Online
Table S4). The cumulative 3-year incidence of stent
or scaffold thrombosis was also numerically higher in
the BVS arm than in the CoCr-EES arm (3.6% vs. 1.6%;
p ¼ 0.17): there were 4 BVS thromboses and 2
TABLE 1 Continued
BVS CoCr-EES
p ValueNumber of Lesions Number of Lesions
OCT
Minimum scaffold/stent area (abluminal), mm2
Post-procedure 81 6.55  1.99 43 6.90  2.44 0.4
At 2 yrs 77 6.31  2.05 38 7.11  2.42 0.07
At 3 yrs 131 6.13  2.03 66 7.15  2.16 <0.001
Neointimal area (on top of/in-between strut), mm2
At 2 yrs 77 2.08  0.66 38 1.82  0.67 0.05
At 3 yrs 131 2.10  0.61 66 1.86  0.64 0.01
Minimum ﬂow area, mm2
Post-procedure 81 5.60  1.81 43 5.95  2.23 0.35
At 2 yrs 77 4.10  1.79 38 5.05  1.97 0.01
At 3 yrs 131 4.02  1.74 66 5.10  2.03 <0.001
Late strut discontinuities
At 2 yrs 77 19 (24.7) 38 0 (0) NA
At 3 yrs 130† 70 (53.8) 64‡ 3 (4.7) <0.001
Healing score
At 2 yrs 77 0.00 (0.00–1.35) 38 0.00 (0.00–1.04) 0.66
At 3 yrs 131 0.00 (0.00–0.00) 66 0.00 (0.00–0.62) 0.06
Lesion with ISA
Post-procedure 81 67 (82.7) 43 40 (93.0) 0.17
At 2 yrs 77 6 (7.8) 38 6 (15.8) 0.19
At 3 yrs 131 13 (9.9) 66 15 (22.7) 0.02
Covered struts, %
At 2 yrs 77 100.0 (99.4–100) 38 100 (99.7–100) 0.44
At 3 yrs 131 100 (100–100) 66 100 (100–100) 1.00
Values are mean  SD, n (%), or median (interquartile range), unless otherwise indicated. *In-device analysis. †One lesion was not analyzable because of incomplete pull-back
length. ‡Two lesions were not analyzable because of artifact.
BVS ¼ bioresorbable vascular scaffold; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent; DS ¼ diameter stenosis; ISA ¼ incomplete strut apposition;
IVUS ¼ intravascular ultrasound; MLD ¼ minimum luminal diameter; NTG ¼ nitroglycerin; NA ¼ not available; OCT ¼ optical coherence tomography; QCA ¼ quantitative
coronary angiography.
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121CoCr-EES thromboses in the ﬁrst year, 4 BVS throm-
boses between 1 and 2 years (16), and 1 BVS throm-
bosis on day 810 in the third year (Figure 1, Online
Table S4, Online Figure S2).
OPTICAL COHERENCE TOMOGRAPHIC FINDINGS.
OCT was performed and analyzable in 124 patients
(BVS, n ¼ 81; CoCr-EES, n ¼ 43) at post-procedure, in
110 patients (BVS, n ¼ 73; CoCr-EES, n ¼ 37) at 2 years,
and in 192 patients (BVS, n ¼ 126; CoCr-EES, n ¼ 66) at
3 years (Online Figure S1). Minimum ﬂow area was
numerically smaller at post-procedure and signiﬁ-
cantly smaller at 2 and 3 years in the BVS arm than in
the CoCr-EES arm (Table 1, Online Table S5). In the
serial analysis, minimum ﬂow area decreased signif-
icantly between 2 and 3 years in the BVS arm but not
in the CoCr-EES arm (Figure 2, Online Table S6).
Minimum scaffold or stent area was also numerically
smaller at post-procedure and signiﬁcantly smaller at
2 and 3 years in the BVS arm than in the CoCr-EES arm
(Table 1, Online Table S5). In the serial analysis,
minimum scaffold or stent area decreased signiﬁ-
cantly between post-procedure and 2 years and be-
tween 2 and 3 years in the BVS arm but not in theCoCr-EES arm (Figure 2). Neointimal area was signif-
icantly larger in the BVS arm than in the CoCr-EES
arm at 3 years (Table 1, Figure 3, Online Table S5). In
the serial analysis, neointimal area in the BVS arm,
but not in the CoCr-EES arm, signiﬁcantly increased
between 2 and 3 years (Figure 2). The decreased
luminal area at follow-up in the BVS arm should be
attributed more to an increase in neointimal
area rather than a decrease in scaffold area
(Online Table S7).
At 3 years, the coverage of struts was complete in
both arms, whereas lesions with incomplete strut
apposition were less frequent in the BVS arm than in
the CoCr-EES arm (Table 1, Online Table S5). Quali-
tative light intensity analysis of neointima demon-
strated that homogeneous neointima was more
frequently observed in the BVS arm than in the CoCr-
EES arm at 3 years (Online Table S5). The healing
score was optimal in both arms (Table 1, Figure 3,
Online Table S5).
At 3 years, strut discontinuities were found in 70
cases (54%) in the BVS arm, 52 of which were covered
and apposed. There were 3 cases with strut disconti-
nuities in the CoCr-EES arm, which were presumably
FIGURE 2 Serial Imaging Observations After Bioresorbable Vascular Scaffold and Cobalt-Chromium Everolimus-Eluting Stent Implantation
(A) Quantitative coronary angiography (QCA), (B) intravascular ultrasound (IVUS), and (C) optical coherence tomography (OCT). Device areas are derived from
abluminal contours. Neointimal areas are presented as on-top of or in-between struts. Only those lesions with paired study were included in this serial analysis. In
patients with interim target lesion revascularization (TLR), pre-TLR quantitative coronary angiography data were carried forward only to the nearest follow-up
quantitative coronary angiographic study for this serial analysis. In serial IVUS and optical coherence tomography analysis, cases with interim TLR were excluded
because of the presence of a nonstudy device. BVS ¼ bioresorbable vascular scaffold; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent; IVUS ¼ intravascular
ultrasound.
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122due to deformation of proximal edge of stent caused
by guiding catheter or other interventional devices
(Online Figure S3). In 18 cases (14%), discontinued
struts were either uncovered and/or malapposed
(intraluminal scaffold dismantling). Of 5 cases with
very late scaffold thrombosis of BVS, strut disconti-
nuities were detected in all 4 cases by OCT performed
just before reintervention (Figure S2, Online Table S8)
(15).
In the serial analysis in the OCT-1 group, there
were 6 lesions (8%) with intraluminal scaffold
dismantling at 2 years, in all of which struts were fully
apposed at post-procedure (Online Figure S4). At 3
years, there were 12 lesions (18%) with intraluminal
scaffold dismantling, in 8 of which there were no
discontinuities or only covered and apposed discon-
tinuities at 2 years, suggesting that new intraluminal
scaffold dismantling occurred between 2 and 3 years
even from struts without any discontinuity (Central
Illustration, Online Tables S5 and S9).QCA AND IVUS FINDINGS. The details of QCA and
IVUS ﬁndings are presented in Table 1, Figures 2 and 3,
and the Online Tables S10 and S11. On quantitative
coronary angiography, change in mean luminal
diameter after intracoronary injection of nitrate was
not signiﬁcantly different between the 2 arms (BVS
0.06  0.11 mm vs. CoCr-EES 0.06  0.11 mm;
p ¼ 0.69) (Online Table S10). In the serial IVUS anal-
ysis, mean vessel area was unchanged not only in the
CoCr-EES arm but also in the BVS arm, suggesting no
positive vessel remodeling in the BVS arm (Figure 2).
There were also few cases with expansive vessel
remodeling in the BVS arm (9.7%) (Online Figure S5).
DISCUSSION
The main ﬁndings in the ABSORB Japan 3-year mul-
timodality serial imaging assessment were the
following: 1) Luminal dimension at 3 years was
smaller in the BVS arm than in the CoCr-EES arm
FIGURE 3 Cumulative Distribution Function Curves of Angiographic Late Lumen Loss and Optical Coherence Tomographic Parameters at
3-Year Follow-Up
(A) Angiographic in-device late lumen loss (LLL); (B) angiographic in-segment LLL; (C) optical coherence tomography (OCT)–derived mean
ﬂow area, abluminal scaffold/stent area, and neointimal area (on top of or in between struts); and (D) OCT-derived healing score.
BVS ¼ bioresorbable vascular scaffold; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent; IQR: interquartile range.
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123because of the combined effects of smaller device and
luminal dimension at post-procedure, further
decrease in scaffold dimension during follow-up, and
greater neointimal formation with the BVS; 2) BVS-
treated vessels did not show previously reported
favorable vessel responses, such as positive vessel
remodeling, late luminal enlargement, and restora-
tion of vasomotion; and 3) intraluminal scaffold
dismantling, suspected as one of the mechanisms of
very late BVS thrombosis, was observed in 14% of
cases at 3 years, 75% of which newly developed be-
tween 2 and 3 years.
The 3-year clinical outcomes in the present study
were consistent with those of other randomized trials
comparing BVS with metallic DES, demonstrating
numeric excess of adverse events such as TLF and
scaffold thrombosis with BVS (17–19). The strength of
the present study was the extensive multimodalityserial imaging assessment after BVS compared with
CoCr-EES implantation in a randomized scheme. The
time course of serial luminal change after device im-
plantation was basically not different between the
BVS and CoCr-EES, with progressive luminal loss
until 2 years, which was somewhat stabilized beyond
2 years. However, luminal dimension was smaller in
the BVS arm than in the CoCr-EES arm throughout the
3-year follow-up period. IVUS and OCT in the present
study provided important information on the serial
changes in device and vessel wall geometry, shedding
light on the mechanisms of the different luminal di-
mensions between BVS and CoCr-EES. The QCA,
IVUS, and optical coherence tomographic ﬁndings in
the present study were generally concordant with one
another, although there were some minor differences
between the imaging modalities. The smaller luminal
dimension with the BVS relative to the CoCr-EES was,
CENTRAL ILLUSTRATION A Representative Case With Late Acquired Strut Malapposition and
Discontinuity of Bioresorbable Vascular Scaffold and Changes in the Frequency of Late Discontinuity
With Serial Optical Coherence Tomography at 2 and 3 Years
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(A–I) A representative case with late acquired strut malapposition and discontinuity of bioresorbable vascular scaffold (BVS). Each cross-
sectional image at 3-year follow-up was matched with a cross section at 2-year follow-up and at post-procedure (A, D, and G; B, E, and H;
and C, F, and I). Struts with incomplete coverage at 2-year follow-up became malapposed at 3-year follow-up (yellow circles in G and H).
Overhung struts were observed at 3-year follow-up (yellow circles in I), whereas these ﬁndings were not observed at 2-year follow-up.
Scaffold areas are calculated with abluminal contours. Asterisk denotes proximal marker. (J) Changes in the frequency of late strut
discontinuity with serial optical coherence tomography (OCT) at 2 and 3 years in 67 scaffolds. Two lesions with malapposed and uncovered
discontinuity observed at 2-year follow-up did not have analyzable OCT for the purpose of strut assessments at 3 years. These 2 lesions are
not presented in these serial observations. ISA ¼ incomplete strut apposition; L ¼ number of lesions.
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125in totality, due to the combined effects of smaller
device and luminal dimension at post-procedure,
further decrease in scaffold dimension during
follow-up, and greater neointimal formation in BVS.
The smaller device area post-implantation was pre-
sumably due to the limited mechanical property of
BVS (5) and/or a relatively conservative optimization
strategy for BVS compared with CoCr-EES. Further
improvement of BVS targeting less acute and chronic
recoil would be required to optimize the luminal
outcome of BVS.
Previous small single-arm imaging studies have
reported positive vessel remodeling, late luminal
enlargement, and restoration of vasomotion during
the resorption phase of BVS (5,17,20). We did not ﬁnd
any of those favorable vessel responses at 3 years in
this large multimodality imaging study with a ran-
domized scheme between BVS and metallic DES,
although a complete healing response and dominance
of homogeneous neointimal formation were observed
in the BVS arm. The possible reason for absence of
positive vessel remodeling may be attributed to
relatively small sample size or use of different IVUS
system between baseline and follow-up.
Very late scaffold thrombosis beyond 1 year is a
major safety issue with BVS; however, its causative
mechanism is still unclear. Previous optical coher-
ence tomographic studies have suggested a high
prevalence of intraluminal scaffold dismantling at the
time of very late BVS thrombosis (21,22). In the pre-
sent study, OCT also revealed the structural discon-
tinuities (either covered or uncovered) in all cases at
the time of very late BVS thrombosis. Malapposed,
uncovered, and disrupted struts in direct contact with
blood ﬂow might have a major bearing on the occur-
rence of very late BVS thrombosis (23). In the present
study, intraluminal scaffold dismantling was
observed in 14% of cases at 3 years. It is currently
unknown whether the intraluminal scaffold disman-
tling observed beyond 1 year stems from persistently
malapposed struts at post-implantation or from late
acquired malapposition. Importantly, the present
serial optical coherence tomographic analysis
demonstrated that intraluminal scaffold dismantling
developed at 2 years even if struts were fully apposed
at post-procedure, and it newly developed between 2
and 3 years, suggesting that optimizing struts appo-
sition at time of implantation could not eliminate late
intraluminal scaffold dismantling. To prevent very
late BVS thrombosis, it is therefore of paramount
importance to reduce intraluminal scaffold disman-
tling by enhancing early tissue encapsulation of the
struts before the structure lose mechanical integrity
during bioresorption. Those ﬁndings would alsosupport prolonged dual-antiplatelet therapy at least
up to 3 years in patients with BVS implantation,
except in patients with high bleeding risk.
In the previous ABSORB Cohort A trial, late dis-
continuities and dismantling were not observed and
were likely underestimated because of: 1) low image
quality of time-domain OCT; 2) no established
method to detect discontinuities and dismantling; 3) a
limited number of serial optical coherence tomo-
graphic imaging studies; and 4) suboptimal timing of
OCT in relation to the bioresorption duration. To avoid
any underestimation of late discontinuities and
dismantling, systematic serial intracoronary OCT up to
the end of bioresorption is indispensable. Such imag-
ing should be applied to early clinical investigation of a
new bioresorbable scaffold.
These observations may entail further iteration of
polymeric bioresorbable scaffolds. Scaffold discon-
tinuities themselves are an inevitable phenomenon
associated universally with bioresorption process
(24), but early encapsulation of struts could be
achieved by making struts smaller and biodegrada-
tion time shorter. For example, a new bioresorbable
scaffold made from post-processed polymer with
improved tensile strength has stronger and thinner
struts and may achieve better embedment and
earlier strut encapsulation without compromising
acute and late recoil (5). As dismantling occurs in
the ﬁnal phase of bioresorption, future pivotal trials
of new bioresorbable scaffolds would need long-
term follow-up until the device completely bio-
degrades, to ensure that the intraluminal disman-
tling does not exist at the end of bioresorption
process (25).
The impact of implantation technique was recently
investigated in the pooled population (n ¼ 2,973) of
the ABSORB trials, including the ABSORB Japan
cohort. BVS implantation in properly sized vessels
was an independent predictor of freedom from scaf-
fold thrombosis through 1 year (hazard ratio: 0.36;
p ¼ 0.004), whereas aggressive pre-dilation was an
independent predictor of freedom from scaffold
thrombosis between 1 and 3 years (hazard ratio: 0.44;
p ¼ 0.03). Because of the lack of prospective in-
struction for the PSP technique, the PSP was opti-
mally performed in only 155 of 3,096 lesions (5.0%),
as in the present study (5.8%). Recently in the AIDA
trial, including an all-comers population treated with
ABSORB, the lesion-level event rate of PSP-treated
lesions did not differ from that of non-PSP-treated
lesions (5.6% vs. 7.1%; p ¼ 0.492). Without prospec-
tive implementation of the PSP strategy, these results
from retrospective analyses preclude drawing deﬁ-
nite conclusions. In addition, the presence of late
PERSPECTIVES
WHAT IS KNOWN? In the ABSORB Japan trial,
randomizing 400 patients in a 2:1 ratio to treatment
with a BVS or a CoCr-EES, 3-year serial comprehensive
imaging with IVUS and OCT demonstrated that
luminal dimension at 3 years was consistently smaller
with the BVS than with the CoCr-EES.
WHAT IS NEW? New occurrence of intraluminal
dismantling between 2 and 3 years was observed by
serial OCT after percutaneous coronary intervention
with the BVS.
WHAT IS NEXT? The development of a new-
generation bioresorbable scaffold with thinner and
narrower struts is ongoing. Any new scaffold should
eliminate late dismantling, in reference to the present
data.
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126acquired strut malapposition demonstrated in the
present study suggests that even optimal post-
procedural results by PSP may not guarantee
freedom from future scaffold dismantling.
STUDY LIMITATIONS. First, the study was under-
powered to detect difference in clinical outcomes
between the BVS and CoCr-EES. Second, post-
procedure OCT and IVUS were performed primarily
for documentary purpose, but not for optimization of
scaffold expansion. Third, the included patients had
mainly stable coronary artery disease and noncom-
plex lesions, precluding the generalizability of the
study ﬁndings to patients with complex lesions.
Fourth, use of multiple types of IVUS and optical
coherence tomographic devices could confound the
absolute measurement of area, although the same
system was used for serial follow-up. Because of the
bioresorption, IVUS could not differentiate the struts,
so that scaffold area was not delineated. Fifth, lesions
with interim TLR were excluded from the serial IVUS
and optical coherence tomographic analysis because
of the presence of a nonstudy device, whereas pre-
TLR QCA data were carried forward up to the 3-year
follow-up QCA study for the nonserial analysis,
which might lead to overestimation of luminal di-
mensions in IVUS and optical coherence tomographic
analysis. Last, this was an interim analysis at 3 years;
the planned 5-year follow-up will provide further
information on the long-term clinical outcomes of
the BVS.
CONCLUSIONS
In this multimodality serial imaging study, luminal
dimension at 3 years was smaller with the BVS than
with the CoCr-EES because of the combined effects ofsmaller device and luminal dimension at post-
procedure, further decrease in scaffold dimension
during follow-up, and greater neointimal formation
in the BVS. Intraluminal scaffold dismantling, sus-
pected as one of the mechanisms of very late BVS
thrombosis, was observed in a substantial proportion
of cases at 3 years, which could newly develop be-
tween post-procedure and 2 years and even beyond 2
years.
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